MerLion's finafloxacin progresses for severe infections after positive IV results
This article was originally published in Scrip
Executive Summary
Early clinical results with an intravenous formulation of MerLion Pharmaceuticals' finafloxacin indicate good potential for the use of the novel fluoroquinolone antibacterial in critical care settings, and further studies in severe, hospital-treated bacterial infections are now getting underway.